Recent Updates
Recently added Catalysts
ANIP Positive Sentiment

ANI Pharmaceuticals to Discuss Third Quarter 2026 Financial Results on November 5, 2026 at 8:00 a.m. ET

Key Takeaway: ANI Pharmaceuticals announced it will release its third quarter 2026 financial results on November 5, 2026, at 8:00 a.m. ET. The event will feature a webcast and conference call led by key executives. The archived webcast will be available for one year on the company's website.

Market Sentiment Analysis

POSITIVE FACTORS

  • ANI Pharmaceuticals will release Q3 2026 results.
  • Webcast and conference call will provide insights.
  • Company focuses on innovative therapeutics.

BiopharmaWatch Analysis

From our catalyst data and publicly available data · not financial advice
Best trade, last catalyst
+64%
120-day peak, hindsight
Typical move
1.9%
average across 4 past catalysts
Lead asset
Fluocinolone Acetonide/Medidur
Phase 3 · Diabetic Macular Edema

Full Press Release Details

PRINCETON, N.J., Oct. 23, 2026 (GLOBE NEWSWIRE) -- ANI Pharmaceuticals, Inc. (Nasdaq: ANIP) (ANI or the Company) today announced that the Company will release its third quarter 2026 financial results on Thursday, November 5, 2026, at 8:00 a.m. ET.
Nikhil Lalwani, President and Chief Executive Officer, Stephen P. Carey, Senior Vice President, Finance, and Chief Financial Officer, and Chris Mutz, Head of Rare Disease will host a webcast and conference call to discuss the results.
Date November 5, 2026
Time 8:00 a.m. ET
Dial-In +1 (833) 630-1956 (U.S. & Canada) +1 (412) 317-1837 (International) Reference the “ANI Pharmaceuticals Third Quarter 2026 Earnings Call.”
Webcast (live and replay) Please click here.
The live and archived webcast will also be available on the “Events & Presentations” page of the Company’s website at https://www.anipharmaceuticals.com, under the “Investors” section. A replay of the event will remain accessible for up to one year.

About ANI

ANI Pharmaceuticals, Inc. (Nasdaq: ANIP) is a diversified biopharmaceutical company committed to its mission of “Serving Patients, Improving Lives" by developing, manufacturing, and commercializing innovative and high-quality therapeutics. The Company is focused on delivering sustainable growth through its Rare Disease business, which markets novel products in the areas of ophthalmology, rheumatology, nephrology, neurology, and pulmonology; its Generics business, which leverages R&D expertise, operational excellence, and U.S.-based manufacturing; and its Brands business. For more information, visit https://www.anipharmaceuticals.com.

Investor Relations: Irina Koffler, Vice President, Investor Relations T: 917-734-7387 E: Irina.koffler@anipharmaceuticals.com

Media Relations: Argot Partners T: 212-600-1494 E: ani@argotpartners.com

SOURCE: ANI Pharmaceuticals, Inc.

Frequently Asked Questions

When will ANI Pharmaceuticals release its Q3 2026 results?

ANI Pharmaceuticals will release its Q3 2026 results on November 5, 2026.

Who will host the conference call for the results?

The call will be hosted by Nikhil Lalwani and other executives.

Where can I access the webcast of the results?

The webcast will be available on the company's website under 'Events & Presentations.'

How long will the archived webcast be available?

The archived webcast will be accessible for up to one year.

Last updated: Oct 23, 2026